Accelovance, a therapeutically focused CRO, has been named a finalist for two Vaccine Industry Excellence (ViE) Awards, with nominations for "Best Contract Research Organization" and "Best Clinical Trial Network and Site."

This is the seventh consecutive year Accelovance has been honored as an award nominee at the World Vaccine Congress, winning for "Best Contract Research Organization" in 2009, 2010 and 2011, as well as receiving a "Highly Recommended" distinction in 2013.

"We're honored to be nominated for these two awards, which highlight the continued depth and breadth of our leadership and experience within the conduct of vaccine trials. Our dedication to serving the needs and advancing the research of sponsors in this important therapeutic area continues to be validated by this global conference distinction," said Stephen J. Trevisan, Accelovance president and CEO.

Accelovance will be evaluated by an international panel for quality of services, performance, client satisfaction, sponsor relationships and the overall value brought to study sponsors. Accelovance is known within the industry for its experience in managing vaccine trials, for successful clinical oversight, patient enrollment and retention and for providing full service solutions to sponsors. Award winners will be announced at the 14th Annual World Vaccine Congress being held in Washington, D.C. March 24-26.